Your browser doesn't support javascript.
Prioritisation by FIT to mitigate the impact of delays in the 2-week wait colorectal cancer referral pathway during the COVID-19 pandemic: a UK modelling study.
Loveday, Chey; Sud, Amit; Jones, Michael E; Broggio, John; Scott, Stephen; Gronthound, Firza; Torr, Beth; Garrett, Alice; Nicol, David L; Jhanji, Shaman; Boyce, Stephen A; Williams, Matthew; Barry, Claire; Riboli, Elio; Kipps, Emma; McFerran, Ethna; Muller, David C; Lyratzopoulos, Georgios; Lawler, Mark; Abulafi, Muti; Houlston, Richard S; Turnbull, Clare.
  • Loveday C; Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
  • Sud A; Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
  • Jones ME; Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
  • Broggio J; National Cancer Registration and Analysis Service, Public Health England, London, UK.
  • Scott S; RM Partners, West London Cancer Alliance, London, UK.
  • Gronthound F; Microbiology, Royal Marsden NHS Foundation Trust, London, UK.
  • Torr B; Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
  • Garrett A; Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
  • Nicol DL; Urology Unit, Royal Marsden NHS Foundation Trust, London, UK.
  • Jhanji S; Division of Clinical Studies, Institute of Cancer Research, London, UK.
  • Boyce SA; Department of Anaesthesia, Perioperative Medicine and Critical Care, Royal Marsden NHS Foundation Trust, London, UK.
  • Williams M; Division of Cancer Biology, Institute of Cancer Research, London, UK.
  • Barry C; Department of Colorectal Surgery, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Riboli E; Department of Clinical Oncology, Imperial College Healthcare NHS Trust, London, UK.
  • Kipps E; Computational Oncology Group, Imperial College London, London, UK.
  • McFerran E; RM Partners, West London Cancer Alliance, London, UK.
  • Muller DC; School of Public Health, Imperial College London, London, UK.
  • Lyratzopoulos G; RM Partners, West London Cancer Alliance, London, UK.
  • Lawler M; The Breast Unit, Royal Marsden NHS Foundation Trust, London, UK.
  • Abulafi M; Patrick G Johnston Centre for Cancer Research, Queens University Belfast, Belfast, UK.
  • Houlston RS; The Breast Unit, Royal Marsden NHS Foundation Trust, London, UK.
  • Turnbull C; National Cancer Registration and Analysis Service, Public Health England, London, UK.
Gut ; 70(6): 1053-1060, 2021 06.
Article in English | MEDLINE | ID: covidwho-733147
ABSTRACT

OBJECTIVE:

To evaluate the impact of faecal immunochemical testing (FIT) prioritisation to mitigate the impact of delays in the colorectal cancer (CRC) urgent diagnostic (2-week-wait (2WW)) pathway consequent from the COVID-19 pandemic.

DESIGN:

We modelled the reduction in CRC survival and life years lost resultant from per-patient delays of 2-6 months in the 2WW pathway. We stratified by age group, individual-level benefit in CRC survival versus age-specific nosocomial COVID-19-related fatality per referred patient undergoing colonoscopy. We modelled mitigation strategies using thresholds of FIT triage of 2, 10 and 150 µg Hb/g to prioritise 2WW referrals for colonoscopy. To construct the underlying models, we employed 10-year net CRC survival for England 2008-2017, 2WW pathway CRC case and referral volumes and per-day-delay HRs generated from observational studies of diagnosis-to-treatment interval.

RESULTS:

Delay of 2/4/6 months across all 11 266 patients with CRC diagnosed per typical year via the 2WW pathway were estimated to result in 653/1419/2250 attributable deaths and loss of 9214/20 315/32 799 life years. Risk-benefit from urgent investigatory referral is particularly sensitive to nosocomial COVID-19 rates for patients aged >60. Prioritisation out of delay for the 18% of symptomatic referrals with FIT >10 µg Hb/g would avoid 89% of these deaths attributable to presentational/diagnostic delay while reducing immediate requirement for colonoscopy by >80%.

CONCLUSIONS:

Delays in the pathway to CRC diagnosis and treatment have potential to cause significant mortality and loss of life years. FIT triage of symptomatic patients in primary care could streamline access to colonoscopy, reduce delays for true-positive CRC cases and reduce nosocomial COVID-19 mortality in older true-negative 2WW referrals. However, this strategy offers benefit only in short-term rationalisation of limited endoscopy services the appreciable false-negative rate of FIT in symptomatic patients means most colonoscopies will still be required.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Colorectal Neoplasms / Cross Infection / Colonoscopy / Risk Assessment / Delayed Diagnosis / COVID-19 / Occult Blood Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Humans Country/Region as subject: Europa Language: English Journal: Gut Year: 2021 Document Type: Article Affiliation country: Gutjnl-2020-321650

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Colorectal Neoplasms / Cross Infection / Colonoscopy / Risk Assessment / Delayed Diagnosis / COVID-19 / Occult Blood Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Humans Country/Region as subject: Europa Language: English Journal: Gut Year: 2021 Document Type: Article Affiliation country: Gutjnl-2020-321650